November 12, 2014

Aviv Biomedical is in the final period of its NIH funded SBIR Phase II grant (5R44EB015924-03), awarded for the development of the bilirubin hematofluorometer. Beta instruments have been made and placed into research at Stanford University. Publications are in progress.The results were in excellent agreement with past versions of this instrument, and correlates were drawn to existing methodologies.1, 2

Aviv is now in the process of expanding research to additional facilities. Additional research funding will be sought to aid with demonstration of the technique’s usefulness, and to develop the device’s final form.

Neonatal hyperbilirubinemia and jaundice occur in almost all newborns and may be benign if its progression to extreme hyperbilirubinemia is recognized, monitored, and prevented or managed in a timely manner.3 It is our hope that the hematofluorometer will be able to provide aid with the more accurate and faster diagnosis of hyperbilirubinemia.

References:

1 Lamola AA, Fanaroff  AA. “Bilirubin fluorescence and prevention of kernicterus.” (1984) Diagn Med 7:9-12

2 Accepted for publication

3 Bhutani, V. K., A. Zipursky, H. Blencowe, R. Khanna, M. Sgro, F. Ebbesen, J. Bell, R. Mori, T. M. Slusher, N. Fahmy, V. K. Paul, L. Du, A. A. Okolo, M.-F. d. Almeida, B. O. Olusanya, P. Kumar, S. Cousens and J. E. Lawn (2013) "Neonatal hyperbilirubinemia and Rhesus disease of the newborn: incidence and impairment estimates for 2010 at regional and global levels." Pediatric Research 74(S1): 86-100


 

July 1, 2012

Aviv Biomedical Inc. has been awarded a Phase II Small Business Innovation Research Grant (SBIR) for a Point of Care System for Determination of Bilirubin Binding Capacity in Neonates.

Public Health Relevance:

Kernicterus is a preventable brain injury in neonates; it is re-emerging in the USA.1 Present day methods of assaying bilirubin do not take into account a child's ability to safely sequester bilirubin and must be interpreted in terms of gestational age, age, weight and other factors.2 The proposed instrument called, Hematofluorometer, directly measures bilirubin binding and reserve bilirubin binding capacity. It has the potential to be faster, less expensive, and available at the point of care.

References:

1 "Research on Prevention of Bilirubin-Induced Brain Injury and Kernicterus: National Institute of Child Health and Human Development Conference Executive Summary" (2004) LR Blackmon, AA Fanaroff, TNK Raju, Pediatrics V 114, pp. 229-233

2 "Influence of clinical status on the association between plasma total and unbound bilirubin and death or adverse neurodevelopmental outcomes in extremely low birth weight infants" (2010) W Oh, DK Stevenson, JE Tyson, BH Morris, CE Ahlfors, G Jesse Bender, RJ Wong, R Perritt, BR Vohr, KP Van Meurs, HJ Vreman, A Das, DL Phelps,  O’Shea, T Michael, RD Higgins, On Behalf of the NICHD Neonatal Research Network Bethesda MD,
Acta Paediatrica V 99, pp. 673-678


Research reported in this press release is supported by the National Institute of Biomedical Imaging and Bioengineering of the National Institutes of Health under Award Number R44EB015924. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.